Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Caroline A. Nebhan & Douglas B. Johnson. (2021) Pembrolizumab in the adjuvant treatment of melanoma: efficacy and safety. Expert Review of Anticancer Therapy 21:6, pages 583-590.
Read now
Read now
Oriol Solà-Morales, Timm Volmer & Lorenzo Mantovani. (2019) Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Articles from other publishers (15)
Collin M. Blakely, Walter Weder, Lukas Bubendorf, Jianxing He, Margarita Majem, Yu Shyr & Jamie E. Chaft. (2023) Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. Lung Cancer 177, pages 59-72.
Crossref
Crossref
Guillermo Villacampa, Pablo Cresta Morgado, Victor Navarro, Cristina Viaplana & Rodrigo Dienstmann. (2023) Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy. Cancer Treatment Reviews, pages 102542.
Crossref
Crossref
Hengliang Xu, Guangqiang Zhao, Jixing Lin, Qianwen Ye, Jia Xiang & Bing Yan. (2023) A combined preoperative red cell distribution width and carcinoembryonic antigen score contribute to prognosis prediction in stage I lung adenocarcinoma. World Journal of Surgical Oncology 21:1.
Crossref
Crossref
Yasuhiro Tsutani, Jonathan W. Goldman, Sanja Dacic, Yasushi Yatabe, Margarita Majem, Xiangning Huang, Allen Chen, Toon van der Gronde & Jie He. (2023) Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer.
Crossref
Crossref
Tiantian Hua, Yuan Gao, Ruyang Zhang, Yongyue Wei & Feng Chen. (2022) Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. BMC Cancer 22:1.
Crossref
Crossref
Fares Alsawah & Dipesh Uprety. (2022) Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC. International Journal of Cancer Care and Delivery 2:1.
Crossref
Crossref
James R. Hébert. 2022. Diet, Inflammation, and Health. Diet, Inflammation, and Health
163
225
.
Yuki Nakagawa, Takuya Yoshimoto, Shintaro Nakagawa, Yasuo Sugitani, Hideharu Yamamoto & Takashi Asakawa. (2021) Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival. Therapeutic Innovation & Regulatory Science 55:6, pages 1258-1264.
Crossref
Crossref
C. Gauvain. (2021) Essais contrôlés randomisés : quelques clés méthodologiques pour comprendre. Revue des Maladies Respiratoires Actualités 13:2, pages 2S55-2S62.
Crossref
Crossref
Hongyu Wang, Bin Li, Yu Wang, Jiang Zhang, Yanqin Wu, Wenzhe Fan & Jiaping Li. (2020) Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization. Journal of Cancer Research and Therapeutics 16:2, pages 301-308.
Crossref
Crossref
Sean Khozin, Rebecca A. Miksad, Johan Adami, Mariel Boyd, Nicholas R. Brown, Anala Gossai, Irene Kaganman, Deborah Kuk, Jillian M. Rockland, Richard Pazdur, Aracelis Z. Torres, Jizu Zhi & Amy P. Abernethy. (2019) Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer. Cancer 125:22, pages 4019-4032.
Crossref
Crossref
Federico M. Goodsaid. (2019) The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics. Clinical and Translational Science 12:5, pages 431-439.
Crossref
Crossref
Urania Dafni, Zoi Tsourti, Katerina Vervita & Solange Peters. (2019) Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 134, pages 127-140.
Crossref
Crossref
Misaki Iijima, Navchaa Gombodorj, Yoshiaki Tachibana, Kohsuke Tachibana, Takehiko Yokobori, Kyoko Honma, Takashi Nakano, Takayuki Asao, Ryusuke Kuwahara, Kazuhiro Aoyama, Hidehiro Yasuda, Matthew Kelly, Hiroyuki Kuwano & Dai Yamanouchi. (2018) Development of single nanometer-sized ultrafine oxygen bubbles to overcome the hypoxia-induced resistance to radiation therapy via the suppression of hypoxia-inducible factor‑1α. International Journal of Oncology.
Crossref
Crossref
Barbara Fingleton, Kelly Lange, Beth Caldwell & Katherine V. Bankaitis. (2018) Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example. Clinical & Experimental Metastasis 34:8, pages 443-447.
Crossref
Crossref